Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
March 07 2023 - 8:30AM
Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a
commercial-stage biopharmaceutical company that focuses on the
development and commercialization of pharmaceutical products for
the treatment of dermatological conditions, today announced that
management will participate in the 35th Annual ROTH Conference,
which is being held March 12-14, 2023.
More specifically, Claude Maraoui, President and
Chief Executive Officer, will partcipate in a fireside chat on
Tuesday, March 14 at 9:30 a.m. PT and will be available for
one-on-one meetings throughout the conference.
A webcast of the company’s fireside chat will be
available on the News and Events page of the Investors section of
Journey Medical’s website, www.journeymedicalcorp.com, for
approximately 30 days after the meeting.
About Journey Medical
CorporationJourney Medical Corporation (Nasdaq: DERM)
(“Journey Medical”) is focused on identifying, acquiring,
developing and strategically commercializing innovative,
differentiated dermatology products through its efficient sales and
marketing model. The company currently markets eight products that
help treat and heal common skin conditions. The Journey Medical
team comprises industry experts with extensive experience in
developing and commercializing some of dermatology’s most
successful prescription brands. Journey Medical is located in
Scottsdale, Arizona and was founded by Fortress Biotech, Inc.
(Nasdaq: FBIO). Journey Medical’s common stock is registered under
the Securities Exchange Act of 1934, as amended, and it files
periodic reports with the U.S. Securities and Exchange Commission
(“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. As used
below and throughout this press release, the words “we”, “us” and
“our” may refer to Journey Medical. Such statements include, but
are not limited to, any statements relating to our growth strategy
and product development programs and any other statements that are
not historical facts. The words “anticipate,” “believe,”
“estimate,” “may,” “expect,” “will,” “could,” “project,” “intend”
and similar expressions are generally intended to identify
forward-looking statements. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; uncertainties
relating to preclinical and clinical testing; risks relating to the
timing of starting and completing clinical trials, including
disruptions that may result from hostilities in Europe; our
dependence on third-party suppliers; our ability to obtain
additional financing on favorable terms or at all; our ability to
attract, integrate and retain key personnel; the early stage of
products under development; our need for substantial additional
funds; government regulation; patent and intellectual property
matters; competition; potential recovery of funds lost from
previously disclosed cyber security breaches; as well as other
risks described in Part I, Item 1A, “Risk Factors,” in our Annual
Report on Form 10-K filed on March 28, 2022, subsequent Reports on
Form 10-Q, and our other filings we make with the SEC. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in
events, conditions or circumstances on which any such statement is
based, except as may be required by law, and we claim the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995.
Company Contact:Jaclyn
JaffeJourney Medical Corporation(781) 652-4500ir@jmcderm.com
Media Relations Contact:Tony
Plohoros6 Degrees(908)
591-2839tplohoros@6degreespr.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024